Jane Street’s Innate Pharma IPHA Stock Holding History

Jane Street’s Portfolio IPHA Stock Details IPHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$19K	Sell	10,310 -33,055	-76%	-$54.7K	﹤0.01%	11222
2026 Q1	$55.5K	Sell	43,365 -49,388	-53%	-$80.6K	﹤0.01%	10933
2025 Q4	$162K	Buy	+92,753	New	+$179K	﹤0.01%	9877
2024 Q2	–	Sell	-14,554	Closed	-$41.9K	–	9770
2024 Q1	$41.9K	Buy	+14,554	New	+$38.1K	﹤0.01%	8787
2022 Q2	–	Sell	-37,736	Closed	-$127K	–	10205
2022 Q1	$127K	Buy	37,736 +23,012	+156%	+$84.9K	﹤0.01%	9330
2021 Q4	$67K	Sell	14,724 -9,706	-40%	-$51.6K	﹤0.01%	9414
2021 Q3	$151K	Buy	+24,430	New	+$105K	﹤0.01%	9060

Other funds holding IPHA

LPC

Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SmartHarvest Portfolios Poulsbo, Washington $309M AUM

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Jane Street's IPHA Position: Q2 2026 in Review

Jane Street reduced its Innate Pharma (IPHA) stake by 76% in Q2 2026, selling an estimated $54.7K and leaving 10,310 shares worth $19K. The position accounts for ﹤0.01% of the portfolio, ranked #11222.

Jane Street first reported a position in IPHA in Q3 2021 and has held it in 7 quarters since. The position peaked at $162K in Q4 2025. 10 funds tracked by Wall St. Rank hold IPHA as of Q2 2026.

Jane Street held 10,310 shares of Innate Pharma worth $19K as of Q2 2026.
Jane Street sold 33,055 Innate Pharma shares in Q2 2026, an estimated $54.7K.
Innate Pharma made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #11222 holding.
Jane Street first reported a position in Innate Pharma in Q3 2021 and has held it in 7 quarters since.
Jane Street's Innate Pharma position peaked at $162K in Q4 2025.
10 funds tracked by Wall St. Rank held Innate Pharma as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.